Pharmaceutical company Sosei has launched new companies using technology from its 2015 acquisition of Heptares, both of which have received funding from Medicxi.
Japan-based pharmaceutical company Sosei has partnered healthcare venture capital fund Medicxi to form two new independent companies focused on treating neurological diseases.
Medicxi is investing a total of €40m ($45.8m) in the two companies, Orexia and Inexia, which are working on therapies meant to combat neurological diseases by altering G protein-coupled receptors Orexin OX1 and OX2.
The drugs are being developed to prevent the loss of orexin neurons, which have been linked to multiple neurological conditions including narcolepsy.
Both companies will…
